China NMPA Drug Inspection - Ningxia Qiyuan Pharmaceutical Co., Ltd. - Orange-red

This announcement, titled "Announcement on Drug Quality Sampling Inspection Information in Ningxia (No. 02 of 2017)" and published on May 5, 2017, outlines the results of drug sampling inspections conducted by the Ningxia Food and Drug Administration. These inspections were part of the "2017 Regional Drug Sampling Inspection Work Plan." The focus was on traditional Chinese medicine decoction pieces throughout the Ningxia region, with testing performed by the Ningxia Hui Autonomous Region Drug Inspection Institute.

The inspection covered 22 batches across 13 varieties of traditional Chinese medicine decoction pieces from various manufacturers, including Bozhou Yuanguang, Ningxia Northwest Medicinal Materials Technology, Anhui Mengshi, and others. The regulatory framework primarily referenced the "Chinese Pharmacopoeia 2015 Edition, Part I," alongside the "Ningxia Traditional Chinese Medicine Processing Standards 1997 Edition" for specific items.

Crucially, all 22 sampled drug batches were found to be fully compliant with the applicable quality standards. Therefore, no violations or significant issues were identified during this inspection round, and consequently, no corrective actions were required from any of the manufacturers or distributors involved.